2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
40
Colorectal Neoplasms
25
Colonic Neoplasms
10
Brain Neoplasms
8
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Neoplasm Metastasis
6
Rectal Neoplasms
5
Skin Neoplasms
4
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Digestive System Neoplasms
2
Thyroid Neoplasms
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Solid Tumor
1
Skin Diseases
1
Recurrence
1
Rectal Diseases
1
Neurofibromatosis 1
1
Multiple Myeloma
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Interventions
Cyclophosphamide
87
fludarabine
77
fludarabine phosphate
45
Tacrolimus
45
Whole-Body Irradiation
42
Mycophenolic Acid
42
Busulfan
35
Melphalan
32
Antilymphocyte Serum
24
Methotrexate
23
thymoglobulin
22
Standard of Care
22
Rituximab
22
Thiotepa
20
Sirolimus
20
Azacitidine
20
venetoclax
19
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
17
Cytarabine
16
Bortezomib
16
Nivolumab
15
Filgrastim
15
Specimen Handling
14
Dexamethasone
14
Blood Specimen Collection
14
Cyclosporine
13
Surveys and Questionnaires
12
Mesna
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
encorafenib
×
Clear all
NCT01981187
2021-03-26
SIGNATURE
Pfizer
Phase 2
Terminated
12 enrolled
13 charts